EU has Negotiated with Johnson & Johnson and has Purchased 200 Million doses of COVID-19 Vaccine and will Buy More in the Future

On August 13, according to the latest report from Reuters, the European Commission and the U.S. pharmaceutical companies in Brussels unanimously stated publicly that they had concluded tentative negotiations with Johnson & Johnson and purchased 200 million doses of candidate vaccines against the new coronavirus.


According to the EU executive agency, the negotiations also pave the way for future transactions. Once the vaccine is proven safe and effective, all 27 EU countries may begin to purchase vaccines. The committee also said that it might buy another 200 million doses of vaccine. Johnson & Johnson's branch, Janssen, in Belgium also issued a statement saying that it will start contract negotiations with the European Commission and notify the head office to confirm the number of vaccines purchased by the European Commission.

Johnson & Johnson said, 'If the company's vaccine is approved by the regulatory authorities, the committee will be expected to promote the process of allocating vaccine doses among member states.' A Johnson & Johnson executive told Reuters on Tuesday that by the end of 2021 , it can produce up to 1 billion doses of vaccine, and the vaccine may be given at once.

Earlier, according to an exclusive report by Reuters in June, the U.S. company was in in-depth negotiations with the European Union on the supply of the new coronavirus pneumonia vaccine. 'We need a safe and effective vaccine to fight against the new coronavirus, and the economy needs to be promoted and recovered as a result. Today's talks bring us closer to achieving this goal.' European Commission President Ursula von Dlein said in a statement.

At the same time, in July this year, the EU and Sanofi (Sanofi SA) have concluded preliminary negotiations on the purchase of 300 million doses of potential new crown vaccine developed by Sanofi and GlaxoSmithKline Plc.